Earnings History Data for Ocugen (OCGN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Ocugen

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-11-2024	PM		OCGN	Ocugen	294.00	-0.05	-0.05	0.00		0.0	0.0 (0.00%)	0.0	0.0 (0.00%)	0.0 - 0.0	0	0	0

08-11-2024	PM		OCGN	Ocugen, Inc.	285.53	N/A	-0.05	-0.06	Ocugen reports Q3 results [11/8/2024 6:55 AM]	0.9862	-0.09 (-8.69%)	1.10	0.02 (1.83%)	0.35 - 2.11	7,567,099	3,810,000	922,038
Ocugen Q3 2024 Earnings Preview [11/7/2024 11:30 AM] Ocugen secures $30M debt funding [11/7/2024 6:39 AM] Ocugen reports Q3 results [11/8/2024 6:55 AM]
08-08-2024	PM		OCGN	Ocugen, Inc.	333.24	-0.04	-0.06	-0.10	Ocugen GAAP EPS of -$0.04 beats by $0.01, revenue of $1.14M [8/8/2024 6:51 AM]	1.26	0.08 (6.78%)	1.29	0.11 (9.32%)	0.34 - 2.11	3,963,290	6,870,000	148,901
Ocugen Q2 2024 Earnings Preview [8/7/2024 11:02 AM] Ocugen GAAP EPS of -$0.04 beats by $0.01, revenue of $1.14M [8/8/2024 6:51 AM]
14-05-2024	PM		OCGN	Ocugen, Inc.	409.15	-0.05	-0.06	-0.07	Ocugen GAAP EPS of -$0.05 beats by $0.01, revenue of $1.01M [5/14/2024 8:02 AM]	1.71	-0.10 (-5.52%)	1.66	-0.15 (-8.29%)	0.34 - 2.11	8,083,059	7,030,000	541,746
Ocugen Q1 2024 Earnings Preview [5/13/2024 12:08 PM] Ocugen GAAP EPS of -$0.05 beats by $0.01, revenue of $1.01M [5/14/2024 8:02 AM]
09-11-2023	PM		OCGN	Ocugen, Inc.	97.36	-0.06	-0.08	-0.10	Ocugen GAAP EPS of -$0.06 beats by $0.01 [11/9/2023 6:32 AM]	0.3613	-0.02 (-5.98%)	0.39	0.0 (0.21%)	0.34 - 1.83	1,318,659	1,180,000	47,480
Ocugen Q3 2023 Earnings Preview [11/8/2023 12:42 PM] Ocugen GAAP EPS of -$0.06 beats by $0.01 [11/9/2023 6:32 AM]
05-05-2023	PM	7:30 AM ET (May 5)	OCGN	Ocugen, Inc.	153.16	-0.07	-0.11	-0.09	Ocugen GAAP EPS of -$0.07 beats by $0.04 [5/5/2023 7:02 AM]	0.7028	0.01 (1.12%)	0.72	0.03 (4.16%)	0.67 - 3.11	4,568,721	5,920,000	299,201
Ocugen Q1 2023 Earnings Preview [5/4/2023 12:44 PM] Ocugen GAAP EPS of -$0.07 beats by $0.04 [5/5/2023 7:02 AM]
28-02-2023	PM	7:30 AM ET (Feb 28)	OCGN	Ocugen, Inc.	221.08	-0.10	-0.11	-0.07	Ocugen GAAP EPS of -$0.10 in-line [2/28/2023 7:03 AM]	1.00	0.03 (2.97%)	0.98	0.0 (0.30%)	0.93 - 4.03	5,077,616	5,420,000	1,176,355
Ocugen Q4 2022 Earnings Preview [2/27/2023 5:48 PM] Ocugen GAAP EPS of -$0.10 in-line [2/28/2023 7:03 AM]
08-11-2022	PM	7:30 AM ET (Nov 8)	OCGN	Ocugen, Inc.	342.17	-0.10	-0.10	-0.05	Ocugen GAAP EPS of -$0.10 in-line [11/8/2022 7:36 AM]	1.65	0.12 (7.84%)	1.57	0.04 (2.61%)	1.52 - 10.40	4,220,343	4,360,000	56,577
Ocugen Q3 2022 Earnings Preview [11/7/2022 1:12 PM] Ocugen GAAP EPS of -$0.10 in-line [11/8/2022 7:36 AM] Ocugen rises 9% after Q3 loss in-line with estimates [11/8/2022 11:13 AM] Ocugen, Inc.'s (NASDAQ:OCGN) largest shareholders are individual investors with 58% ownership, institutions own 40% [Nov-07-22 08:17AM] Ocugen Provides Business Update & Third Quarter 2022 Financial Results [Nov-08-22 07:30AM]
05-08-2022	PM	6:35 AM ET (Aug 5)	OCGN	Ocugen, Inc.	519.75	-0.09	-0.08	-0.13	Ocugen GAAP EPS of -$0.09 misses by $0.01 [8/5/2022 7:31 AM]	2.86	0.09 (3.25%)	2.86	0.0 (0.00%)	1.67 - 17.65	5,819,715	4,520,000	5,267
Ocugen Q2 2022 Earnings Preview [8/4/2022 1:22 PM] Ocugen GAAP EPS of -$0.09 misses by $0.01 [8/5/2022 7:31 AM]
06-05-2022	PM	7:30 AM ET (May 6)	OCGN	Ocugen, Inc.	539.16	-0.09	0.05	-0.04	Ocugen GAAP EPS of -$0.09 misses by $0.10 [5/6/2022 6:36 AM]	2.16	-0.12 (-5.26%)	2.16	0.0 (0.00%)	2.10 - 17.65	5,700,569	6,440,000	277
Ocugen Q1 2022 Earnings Preview [5/5/2022 12:02 PM] Ocugen GAAP EPS of -$0.09 misses by $0.10 [5/6/2022 6:36 AM] Ocugen Provides Business Update and First Quarter 2022 Financial Results [May-06-22 06:33AM] Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates [May-06-22 07:45AM] Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript [May-06-22 12:30PM]
25-02-2022	PM	7:30 AM ET (Feb 25)	OCGN	Ocugen, Inc.	842.56	-0.07	-0.07	0.00	Ocugen GAAP EPS of -$0.07 in-line [2/25/2022 7:31 AM]	3.17	0.12 (3.93%)	3.17	0.12 (3.76%)	2.87 - 17.65	9,806,761	17,200,000	831,831
Ocugen Q4 2021 Earnings Preview [2/24/2022 12:50 PM] Ocugen GAAP EPS of -$0.07 in-line [2/25/2022 7:31 AM] Ocugen bolsters cash even as Q4 expenses rise amid advances in COVID-19 vaccine [2/25/2022 8:12 AM] Ocugen expects $53.5M from stock sale amid efforts to bring Covaxin to the U.S. [Feb-24-22 01:09PM] 3 Growth Stocks With Monster Upside of 253% to 650%, According to Wall Street [Feb-24-22 05:06AM] Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results [Feb-25-22 07:31AM] Ocugen's stock jumps 4% after saying FDA lifted hold on trial for experimental COVID-19 shot [Feb-25-22 07:51AM] Is Ocugen Stock a Buy Now? [Feb-25-22 08:12AM] Ocugen, Inc. (OCGN) Q4 2021 Earnings Call Transcript [Feb-25-22 12:30PM]
09-11-2021	PM	7:30 AM ET (Nov 9)	OCGN	Ocugen, Inc.	2,000	-0.05	-0.04	-0.07	Ocugen EPS misses by $0.01 [11/9/2021 7:34 AM]	8.88	-0.75 (-7.81%)	8.90	-0.73 (-7.58%)	0.28 - 18.77	27,896,533	105,560,000	2,678,410
Ocugen Q3 2021 Earnings Preview [11/8/2021 2:56 PM] Ocugen submits FDA IND application for early-stage OCU400 retinal degeneration study [11/8/2021 9:33 AM] Ocugen EPS misses by $0.01 [11/9/2021 7:34 AM] Ocugen seeks FDA clearance to use COVID-19 vaccine in children [11/9/2021 8:05 AM] Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration [Nov-08-21 09:24AM] Ocugen Seeks FDA Nod for Trial of Its Retinal Degeneration Treatment [Nov-08-21 08:22AM] Where Will Ocugen Be in 3 Years? [Nov-08-21 06:45AM] Ocugen Provides Business Update and Third Quarter 2021 Financial Results [Nov-09-21 07:30AM] Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript [Nov-09-21 05:30PM] Ocugen Stock Looks Poised to Take a Tumble Right Here [Nov-08-21 06:00AM]
06-08-2021	PM	7:30 AM ET (Aug 6)	OCGN	Ocugen, Inc.	1,400	-0.13	-0.03	-0.19	Ocugen EPS misses by $0.10 [8/6/2021 7:36 AM]	7.88	0.39 (5.14%)	7.25	-0.24 (-3.20%)	0.25 - 18.77	28,298,561	12,560,000	1,077,594
Ocugen EPS misses by $0.10 [8/6/2021 7:36 AM] Ocugen Q2 R&D expenses surged driven by licensing cost for COVAXIN in Canada [8/6/2021 8:09 AM] Ocugen-partnered COVID-19 shot undergoes regulatory review in Canada [8/6/2021 3:25 PM] CLASS ACTION UPDATE for OCGN, LOTZ and BLCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [Aug-05-21 02:10PM] SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm [Aug-05-21 11:06AM] SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocugen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2021 - OCGN [Aug-05-21 06:28AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, HMPT and YMM [Aug-05-21 05:40AM] Ocugen Provides Business Update and Second Quarter 2021 Financial Results [Aug-06-21 07:32AM] Ocugen's (OCGN) Q2 Earnings Miss Estimates, Stock Down [Aug-06-21 08:32AM] OCGN BREAKING NOTICE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action OCGN [Aug-06-21 10:37AM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OCGN, QFIN and ATVI [Aug-06-21 11:15AM] Ocugen sees 77.8% efficacy in phase 3 trial for COVID-19 vaccine [Aug-06-21 11:52AM] SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm [Aug-06-21 12:32PM] LAWSUITS FILED AGAINST OCGN, BLCT and ZY - Jakubowitz Law Pursues Shareholders Claims [Aug-06-21 02:00PM] Why Ocugen Is Rallying Today [Aug-06-21 04:01PM] Ocugen, Inc. (OCGN) Q2 2021 Earnings Call Transcript [Aug-06-21 08:01PM]
07-05-2021	PM	7:30 AM ET (May 7)	OCGN	Ocugen, Inc.	2,350	-0.04	0.50	-0.07	Ocugen EPS misses by $0.02 [5/7/2021 7:38 AM]	9.19	-0.39 (-4.12%)	9.18	-0.01 (-0.05%)	0.17 - 18.77	160,781,652	183,010,000	9,664
Ocugen shares fall 14% despite OCU200 shows potential to treat ocular neovascular diseases [5/6/2021 9:18 AM] Ocugen EPS misses by $0.02 [5/7/2021 7:38 AM] Ocugen slips after Q1 results shows rising costs amid progress in COVID-19 vaccine front [5/7/2021 10:39 AM] BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues [May-06-21 12:32PM] Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study [May-06-21 12:28PM] Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN [May-06-21 09:05AM] Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting [May-06-21 07:30AM] Better Vaccine Stock: Ocugen or Vaxart? [May-07-21 06:10AM] Does Ocugen Have a Real Shot at the U.S. COVID Vaccine Market? [May-07-21 06:15AM] Ocugen Inc to Host Earnings Call [May-07-21 06:45AM] Ocugen Provides Business Update and First Quarter 2021 Financial Results [May-07-21 07:30AM] Ocugen (OCGN) Miss Earnings & Revenues Estimates in Q1 [May-07-21 10:44AM] Why Ocugen Stock Is Tanking Today [May-07-21 11:40AM]
18-03-2021	PM	7:30 AM ET (Mar 18)	OCGN	Ocugen, Inc.	1,860	N/A	-0.02	0.00	Ocugen EPS beats by $0.05, beats on revenue [3/18/2021 7:32 AM]	8.92	-0.63 (-6.60%)	9.19	-0.36 (-3.77%)	0.17 - 18.77	30,661,625	36,120,000	1,422,334
Ocugen EPS beats by $0.05, beats on revenue [3/18/2021 7:32 AM] Ocugen in talks with U.S. regulators for emergency use approval for Covaxin [3/18/2021 9:15 AM] 3 Biotech Stocks to Avoid Right Now [Mar-18-21 06:16AM] Ocugen Inc to Host Earnings Call [Mar-18-21 06:30AM] Ocugen Provides Business Update and Full Year 2020 Financial Results [Mar-18-21 07:30AM] What Really Mattered With Ocugen's Q4 Update [Mar-18-21 01:00PM] Top Biotech Stocks for Q2 2021 [Mar-18-21 06:02PM]
06-11-2020	PM	7:30 AM ET (Nov 6)	OCGN	Histogenics Corporation	46.00	-0.07	-0.02	0.00		0.2814	-0.01 (-1.92%)	0.0	0.0 (0.00%)	0.17 - 1.45	4,201,351	2,804,737	0

14-08-2020	PM	7:30 AM ET (Aug 14)	OCGN	Ocugen, Inc.	81.00	-0.19	-0.03	-1.80		0.5599	-0.06 (-10.13%)	0.5770	-0.05 (-7.38%)	0.17 - 17.40	8,374,222	32,874,992	2,548,870